Articles by Andrew Moreno
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Side effects are an important consideration when using bispecific antibodies in this population, Dr. Krina Patel explains.
Risk factors for infection and infection-related mortality were assessed in recipients of CD19 CAR T-cell therapy.
Dr. Krina Patel was part of a comparative study team which evaluated these two therapies' efficacy and safety in MM care.
Ruchi Desai, MD, specifies what improvements are needed today in the therapy options available for myelofibrosis.
Ruchi Desai, MD, speaks on the challenges of clinical evaluation and therapy optimization in myelofibrosis.
Enrolled patients had chronic phase CML without BCR::ABL1 T315I mutation and had undergone at least two prior TKI treatments.
In the RELATIVITY-022 study, the combination's efficacy was greatest in Hodgkin lymphomas naive to PD-1 or PD-L1 inhibition.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
ELEMENT-MDS trial tests luspatercept vs epoetin alfa for anemia in ESA-naive, lower-risk MDS without transfusion need.
Our expert roundtable reacts to data presented at ASCO 2025 on real-world use of the agent in this setting.
Experts discuss what data do clinicians need in order to optimize their first-line use of this agent for low-risk MDS.
Our expert panel reacts to the updated efficacy and safety data for luspatercept presented at ASCO 2025.
Panelists discuss how these biomarkers factor into their therapy choices and the impact of new data from ASCO 2025.
End Point Success Varies in a Phase 3 Trial of Luspatercept Plus JAK Inhibitor Therapy for MF Anemia
The combination did not meet the primary end point for RBC transfusion independence but still markedly improved anemia.
The agent, investigational drug candidate ADX-2191, is a novel intravitreal injection formulation of methotrexate.
The results of the study support use of this agent and give clues on optimal timing and sequencing.
Manali Kamdar, MD, assesses the effect on clinical practice from these label updates for CD19- and BCMA-targeting therapies.
The model estimates patients' 2-year progression-free survival using patient information routinely recorded in the clinic.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.